Mark Versavel

2.1k citations

21 papers · 1.2k indexed · h-index 13

Impact in

Anesthesiology and Pain Medicine top 2%
- Pain Management and Opioid Use
Neurology top 5%
- Botulinum Toxin and Related Neurological Disorders

Papers in ⓘ

Psychiatry and Mental health 10
- Epilepsy research and treatment 5
- Bipolar Disorder and Treatment 4
- Schizophrenia research and treatment 3
Neurology 7
- Botulinum Toxin and Related Neurological Disorders 3

Co-authors: James P. Young (2 shared papers)David A. Cherry (1 shared paper)Pascal Maisonobe (1 shared paper)Emmanuelle Vincent (1 shared paper)Rafael Gálvez (1 shared paper)R. Sabatowski (1 shared paper)Hilary A. Feister (1 shared paper)Malcolm Stoker (1 shared paper)
Journals: Journal of Child and Adolescent Psychopharmacology (2 papers)The Journal of Clinical Psychiatry (2 papers)Alzheimer s & Dementia (1 paper)Sleep Medicine (1 paper)Drug Metabolism and Pharmacokinetics (1 paper)
Partner nations: United States United Kingdom France

In The Last Decade

Mark Versavel

20 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mark Versavel

Since Specialization

Citations

This map shows the geographic impact of Mark Versavel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Versavel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Versavel more than expected).

Fields of papers citing papers by Mark Versavel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Versavel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Versavel. The network helps show where Mark Versavel may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Versavel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Versavel Line = papers co-authored together Mark Versavel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial Pain ·R. Sabatowski, Rafael Gálvez, David A. Cherry, Florence Jacquot, Emmanuelle Vincent, Pascal Maisonobe, Mark Versavel	2004	397
2	Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13‐week, randomized trial Current Medical Research and Opinion ·Robert van Seventer, Hilary A. Feister, James P. Young, Malcolm Stoker, Mark Versavel, Laurence Rigaudy	2006	202
3	Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: A randomized, double‐blind study European Journal of Pain ·Thomas R. Tölle, Rainer Freynhagen, Mark Versavel, Uwe Trostmann, James P. Young	2007	171
4	Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease Clinical Pharmacokinetics ·John A. Hey, Yongxin Yu, Mark Versavel, Susan Abushakra, Petr Kočiš, Aidan Power, Paul L. Kaplan, John Amedio, Martin Tolar	2017	93
5	Ziprasidone Plus a Mood Stabilizer in Subjects With Bipolar I Disorder The Journal of Clinical Psychiatry ·Charles L. Bowden, Eduard Vieta, Kathleen Ice, Jeffrey H. Schwartz, Paul P. Wang, Mark Versavel	2010	93
6	AMPA Antagonist ZK200775 in Patients With Acute Ischemic Stroke Stroke ·Jan‐Willem J. Elting, Geert Sulter, Markku Kaste, Kennedy R. Lees, Hans‐Christoph Diener, Marc Hommel, Mark Versavel, Albert Teelken, Jacques De Keyser	2002	51
7	Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder Journal of Child and Adolescent Psychopharmacology ·Melissa P. DelBello, Mark Versavel, Kathleen Ice, David Keller, Jeffrey Miceli	2008	42
8	The AMPA Antagonist ZK 200775 in Patients with Acute Ischaemic Stroke: A Double-Blind, Multicentre, Placebo-Controlled Safety and Tolerability Study Cerebrovascular Diseases ·Matthew R. Walters, Markku Kaste, Kennedy R. Lees, Hans‐Christoph Diener, Marc Hommel, Jacques De Keyser, Heike Steiner, Mark Versavel	2005	39
9	The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption The Journal of Clinical Psychiatry ·Kuan Gandelman, Jeffrey Alderman, Paul Glue, Ilise Lombardo, Robert R. LaBadie, Mark Versavel, Sheldon Preskorn	2008	38
10	A Phase 2 Proof‐of‐Concept, Randomized, Placebo‐Controlled Trial of CX‐8998 in Essential Tremor Movement Disorders ·Spyros Papapetropoulos, Margaret Lee, Stacey Versavel, Evan Newbold, Hyder A. Jinnah, Rajesh Pahwa, Kelly E. Lyons, Rodger J. Elble, William G. Ondo, Theresa Zesiewicz, Peter Hedera, Adrian Handforth, Jenna Elder, Mark Versavel	2021	21
11	Efficacy and tolerability of sumanirole in restless legs syndrome: A phase II, randomized, double-blind, placebo-controlled, dose–response study Sleep Medicine ·Diego García‐Borreguero, John W. Winkelman, Alieu Adams, Amanda Ellis, Mark Morris, Janice Lamb, Gary Layton, Mark Versavel	2007	17
12	Inclusion and exclusion criteria for epilepsy clinical trials–Recommendations from the April 30, 2011 NINDS workshop Epilepsy Research ·Evan Fertig, Brandy Fureman, Gregory K. Bergey, Mary Ann Brodie, Dale C. Hesdorffer, Deborah Hirtz, Eric H. Kossoff, W. Curt LaFrance, Mark Versavel, Jacqueline A. French	2014	13
13	Giant Aneurysm Arising from the Anterior Cerebral Artery and Causing an Isolated Homonymous Hemianopsia Neurosurgery ·Mark Versavel, Jan P. Witmer, Bart Matricali	1988	13
14	Psychosocial Functioning and Health-Related Quality of Life in Children and Adolescents Treated with Open-Label Ziprasidone for Bipolar Mania, Schizophrenia, or Schizoaffective Disorder Journal of Child and Adolescent Psychopharmacology ·Michelle Stewart, Melissa P. DelBello, Mark Versavel, David Keller	2009	11
15	Evaluation of the Pharmacokinetic Interaction Between the Voltage‐ and Use‐Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers Clinical Pharmacology in Drug Development ·Joi Dunbar, Mark Versavel, Yuan Zhao, Simon Tate, Valérie Morisset, Gerard M.P. Giblin, Joanne Palmer, Beth Tidemann‐Miller, Himanshu Naik	2019	10
16	Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers Clinical and Translational Science ·Himanshu Naik, Deb Steiner, Mark Versavel, Joanne Palmer, Regan Fong	2020	6
17	Phase 1 study to evaluate the absorption, metabolism and excretion of the NAV1.7-selective sodium channel blocker BIIB074 Drug Metabolism and Pharmacokinetics ·Caroline Woodward, Himanshu Naik, Mark Versavel, Lin Xu, Xiaopeng Miao, Hao Sun, Mark Gohdes, Joi Dunbar	2018	4
18	Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP‐432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects CNS Neuroscience & Therapeutics ·John J. Sramek, Larry W. Hardy, P. R. Bieck, Cynthia Zamora, Mark Versavel, Jahnavi Kharidia, Todd Grinnell, Yu‐Luan Chen, Michael P. Sullivan, Hong Ding, Neal R. Cutler	2016	3
19	P2‐012: Phase 1 Development of ALZ‐801, a Novel Beta Amyloid Anti‐Aggregation Prodrug of Tramiprosate with Improved Drug Properties, Supporting Bridging to The Phase 3 Program Alzheimer s & Dementia ·John A. Hey, Susan Abushakra, Aidan Power, Yongxin Yu, Mark Versavel, Martin Tolar	2016	3
20	Efficacy and safety of the novel sodium channel Blocker CNV1014802 in Trigeminal Neuralgia and Lumbosacral Radiculopathy Journal of Pain & Relief ·Mark Versavel	2015	2

About Mark Versavel

Mark Versavel is a scholar working on Psychiatry and Mental health, Neurology, Anesthesiology and Pain Medicine, Pediatrics, Perinatology and Child Health and Pharmacology, having authored 21 papers that have together received 1.2k indexed citations. Recurring topics across this work include Pharmacological Effects and Toxicity Studies (5 papers), Epilepsy research and treatment (5 papers), Bipolar Disorder and Treatment (4 papers), Botulinum Toxin and Related Neurological Disorders (3 papers), Schizophrenia research and treatment (3 papers), Cholinesterase and Neurodegenerative Diseases (3 papers), Pain Mechanisms and Treatments (3 papers) and Alzheimer's disease research and treatments (2 papers). The work is most often cited by research in Anesthesiology and Pain Medicine (177 citations), Neurology (422 citations), Physiology (691 citations), Psychiatry and Mental health (301 citations) and Pharmacology (289 citations). Mark Versavel has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include James P. Young, David A. Cherry, Pascal Maisonobe, Emmanuelle Vincent, Rafael Gálvez, R. Sabatowski, Hilary A. Feister, Malcolm Stoker, Thomas R. Tölle and Rainer Freynhagen. Their work appears in journals such as Journal of Child and Adolescent Psychopharmacology, The Journal of Clinical Psychiatry, Alzheimer s & Dementia, Sleep Medicine and Drug Metabolism and Pharmacokinetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact